Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INMD 
InMode Ltd (INMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: INMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $17.25
Year Target Price $17.25
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.82% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 896.94M USD | Price to earnings Ratio 6.36 | 1Y Target Price 17.05 |
Price to earnings Ratio 6.36 | 1Y Target Price 17.05 | ||
Volume (30-day avg) - | Beta 1.99 | 52 Weeks Range 13.14 - 19.85 | Updated Date 06/29/2025 |
52 Weeks Range 13.14 - 19.85 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 44.79% | Operating Margin (TTM) 20.06% |
Management Effectiveness
Return on Assets (TTM) 8.62% | Return on Equity (TTM) 24.5% |
Valuation
Trailing PE 6.36 | Forward PE 8.48 | Enterprise Value 357100559 | Price to Sales(TTM) 2.29 |
Enterprise Value 357100559 | Price to Sales(TTM) 2.29 | ||
Enterprise Value to Revenue 0.91 | Enterprise Value to EBITDA 3.22 | Shares Outstanding 60918800 | Shares Floating 58178524 |
Shares Outstanding 60918800 | Shares Floating 58178524 | ||
Percent Insiders 15.35 | Percent Institutions 72.44 |
Analyst Ratings
Rating 3.43 | Target Price 17.25 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InMode Ltd
Company Overview
History and Background
InMode Ltd. was founded in 2008. It develops, manufactures, and markets innovative medical technologies. Initial focus was on RF-based aesthetic and surgical solutions. Since inception, InMode has expanded its product portfolio and global reach, focusing on minimally invasive and non-invasive procedures.
Core Business Areas
- Aesthetic Medical Devices: Develops and markets energy-based aesthetic and surgical platforms for various treatments, including skin rejuvenation, body contouring, and hair removal.
- Surgical Medical Devices: Provides minimally invasive surgical solutions for procedures such as facelift, neck lift, and liposuction, utilizing proprietary radiofrequency technology.
- Consumables and Services: Inmode sells consumables related to their devices, and provides post sales service to increase customer satifaction.
Leadership and Structure
The leadership team includes Moshe Mizrahy (CEO), Shakil Amir (CFO), and Michael Kreindel (CTO). The company operates with a functional organizational structure, with departments focusing on R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- BodyTite: A minimally invasive body contouring and liposuction device utilizing RFAL (Radio-Frequency Assisted Lipolysis) technology. It competes with traditional liposuction and other energy-based body contouring devices. The market share for this product is difficult to ascertain precisely, but InMode is a leading provider in the RFAL space. Competitors include Cutera, BTL Industries, and Cynosure.
- Morpheus8: A fractional RF microneedling device for skin resurfacing, collagen remodeling, and wrinkle reduction. InMode is a major player in the RF microneedling market. Competitors include Endymed, Candela, and Lutronic. The exact market share is unavailable, but InMode's Morpheus8 is a well-regarded system in that market. Revenue from Morpheus8 constitutes a significant portion of the companyu2019s revenue, but specific figures are not always disclosed in earnings reports.
- Evolve: A hands-free platform offering non-invasive body contouring and muscle toning treatments. This competes with CoolSculpting by Zeltiq (owned by Allergan) and Emsculpt by BTL. Evolve is a smaller segment of their revenue, the exact percentage is not directly available.
Market Dynamics
Industry Overview
The aesthetic medical device industry is experiencing substantial growth driven by increasing demand for non-invasive and minimally invasive procedures. Key trends include technological advancements, rising disposable incomes, and an aging population seeking cosmetic enhancements. Increased social media awareness helps drive demand in this market.
Positioning
InMode is positioned as a leader in the energy-based aesthetic device market, focusing on innovative RF-based technologies. Its competitive advantages include proprietary technology, a broad product portfolio, and a strong sales and marketing network.
Total Addressable Market (TAM)
The global aesthetic medicine market is projected to reach $147.9 billion by 2029. InMode is positioned to capture a significant share of this market through its innovative technologies and growing market presence. Exact position percentage within the TAM is difficult to ascertain.
Upturn SWOT Analysis
Strengths
- Proprietary RF-based technologies
- Broad product portfolio
- Strong sales and marketing network
- High gross margins
- Recurring revenue from consumables
Weaknesses
- Dependence on regulatory approvals
- Competition from established players
- Risk of product obsolescence
- Geographic concentration of sales.
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary businesses
- Increasing consumer awareness of minimally invasive procedures
Threats
- Increasing competition
- Changes in regulations
- Economic downturns
- Adverse publicity regarding aesthetic procedures
Competitors and Market Share
Key Competitors
- LNC
- ALGN
- ZBH
- HOLX
Competitive Landscape
InMode competes with larger, more established medical device companies, but its proprietary technology and focus on minimally invasive procedures provide a competitive advantage. Inmode has been growing in the market.
Growth Trajectory and Initiatives
Historical Growth: InMode has experienced significant revenue growth over the past few years, driven by strong demand for its products and expansion into new markets.
Future Projections: Analyst estimates project continued revenue and earnings growth for InMode, supported by its innovative product pipeline and expanding market presence. However, the rate of growth may slow as the company matures.
Recent Initiatives: Recent initiatives include expanding its product portfolio, entering new geographic markets, and strengthening its sales and marketing efforts.
Summary
InMode is a growing company in the aesthetic medical device market. The company's proprietary technologies and strong sales network contribute to its growth. Challenges include competition and regulatory hurdles, which InMode needs to be aware of to continue expanding, improving its financial perfomance, and market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry reports
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMode Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-08-08 | Co-Founder, CEO & Director Mr. Moshe Mizrahy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 599 | Website https://www.inmodemd.com |
Full time employees 599 | Website https://www.inmodemd.com | ||
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.